SecBot SecBot

VTVT

vTv Therapeutics Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001641489 Biotech & Drug Discovery
$17.69 −2.00 (−10.16%)
Nov 16 4:00 PM ET · prev $19.69
Market cap
$83.0M
Micro cap
Consensus
Buy
92% Buy or better · 13 analysts
Median target
$57.00
+222% · range $42.00–67.00
1 year
−41.3%
from $30.15 · Nov 17
30 days
−34.3%
from $26.94
52-week range
$17.69–42.72
at the low
Avg volume 20D
22.3K
Nov 12 spike 71.0K
Short interest
145.4K
≈3.6% of shares · +1.4%
Days to cover
8.2
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
7
analyzed by SecBot
SecBot read MIXED 5 reports · 90 days
Balance 0 bearish · 0 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 3/5

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q3 2026: 5 added (0 new), 5 trimmed or exited.

  • AnalystsBULLISH

    12 of 13 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$1.153 → −$1.220 over 90 days. 2 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest +1.4% to 145.4K shares. 8.2 days to cover, ≈3.6% of shares.

  • TrendDOWNTREND

    36% below its 50-day average. New closing low $17.69 on Nov 16.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
GEODE CAPITAL MANAGEMENT, LLCTRIM24,350$751.7K
HRT FINANCIAL LPDOUBLED24,167$745.0K
MARSHALL WACE, LLPTRIM23,883$736.6K
MORGAN STANLEYDOUBLED17,476$539.0K
VANGUARD FIDUCIARY TRUST COTRIM12,129$374.1K
UBS Group AGDOUBLED11,319$349.1K
Vanguard Global Advisers, LLCTRIM337$10.4K
BNP PARIBAS FINANCIAL MARKETSNEAR_EXIT9$278.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

13 analysts
Buy 92% rate it Buy or better
Strong Buy3Buy9Hold1Sell0Strong Sell0
12-month targets · 7 analysts

Price is below the lowest target. Median implies +222%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Oct 14, 2026BTIG
REITERATE
REITERATEBuy
Aug 6, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jul 16, 2026BTIG
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jun 26, 2026
AKKARAJU SRINIVAS
Director
Jun 26, 2026
AWARD$210.5K
Jun 26, 2026
Al-Marzooqi Fahed
Director
Jun 26, 2026
AWARD$210.5K
Jun 26, 2026
Phillips Anne M.
Director
Jun 26, 2026
AWARD$210.5K
Jun 26, 2026
SPIEGELMAN DANIEL K
Director
Jun 26, 2026
AWARD$210.5K
Jun 26, 2026
BAKER BROS. ADVISORS LP
Director
Jun 26, 2026
AWARD6,000 sh

Earnings setup

Estimates
−$1.22
EPS estimate, this quarter
−6%
estimate change, 90 days
2↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.22-$1.46–-$1.04-4.3%$0.00
Next Q-$1.08-$1.21–-$1.00+2.3%$0.00
Current FY-$2.04-$4.07–-$1.09+7.9%$30.7M
Next FY-$3.87-$4.81–-$2.46+17.7%$0.00

Short side

FINRA· Oct 30, 2026
145,417
shares short
+1.4%
vs prior settlement
8.2
days to cover
≈3.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 12, 2026 SEC
Samsara BioCapital, L.P., a major shareholder, filed Form 144 to sell 61,287 shares of vTv Therapeutics common stock…
144 · Impact 3/10
Nov 5, 2026 SEC
vTv Therapeutics reported Q3 2026 net loss of $11.6M ($0.94 per share), wider than the $8.7M loss in Q3 2025, but the…
8-K · Impact 4/10
Nov 5, 2026 Earnings
vTv Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) completed en
Sep 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC · TRIM
24,350 shares ($751.7K)
Sep 30, 2026 Inst.
HRT FINANCIAL LP · DOUBLED
24,167 shares ($745.0K)
Jun 26, 2026 Insider
AKKARAJU SRINIVAS was granted 6,000 shares
Director @ $35.08 ($210.5K)
Jun 26, 2026 Insider
Al-Marzooqi Fahed was granted 6,000 shares
Director @ $35.08 ($210.5K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent
Nov 5, 2026
Earnings
vTv Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) completed enrollment with 166 participants randomized…
Nov 4, 2026
Earnings date
VTVT Q3 2026 Earnings Scheduled · 2026-11-04
Sep 15, 2026
Press release
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
HIGH POINT, N.C., Sept. 15, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the…
Sep 2, 2026
Press release
vTv Therapeutics to Participate in September Investor Conferences
HIGH POINT, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing…
Aug 10, 2026
Earnings date
VTVT Q2 2026 Earnings Scheduled, 2026-08-10

SecBot reports

7 filings · 2 press releases · 0 bullish · 0 bearish · 7 neutral
All VTVT filing & press-release reports (9)